Korean J Gastroenterol.  2004 Dec;44(6):314-320.

Cyclin E, p27 and Mutant p53 do not Predict the Prognosis in AJCC Stage II Colorectal Carcinomas

• Lim YJ
• Kim YH
• Ahn GH
• Chun HK
• Jang WY
• Lee JH
• Son HJ
• Rhee PL
• Kim JJ
• Paik SW
• Yoo BC
• Rhee JC

Abstract

BACKGROUND/AIMS: Carcinogenesis is characterized by the abnormal regulation of cell cycle. The abnormal expression of the regulators of cell cycle may be related to the prognosis. Since the clinical significance of the expression of the three proteins in colorectal carcinomas is still controversial, we evaluated the prognostic value of the expression of cyclin E, p27 and mutant p53 in stage II colorectal cancer. METHODS: The expression levels of cyclin E, p27 and mutant p53 proteins in 41 patients with stage II colorectal carcinomas were analyzed by immunohistochemistry. RESULTS: In the univariate analysis, the level of CEA at diagnosis was associated with disease relapse. In the multivariate analysis, the clinicopathological variables such as age, gender, site of primary tumor, tumor size, state of tumor differentiation and preoperative plasma CEA level were not associated with disease relapse. When Kaplan-Meier survival curves were constructed to determine the prognosis, cyclin E, p27 and mutant p53 expressions did not predict poor prognosis. CONCLUSIONS: Our results suggested that the expression of cyclin E, p27 and mutant p53 proteins did not predict the clinical outcome in the stage II colorectal carcinomas.

Keyword

Cyclin E; p27; Protein p53; Colorectal neoplasm

MeSH Terms

Adenocarcinoma/chemistry/*diagnosis/mortality/pathology
Adult
Aged
Aged, 80 and over
Cell Cycle Proteins/*analysis
Colorectal Neoplasms/chemistry/*diagnosis/mortality/pathology
Cyclin E/*analysis
Disease-Free Survival
Female
Humans
Immunohistochemistry
Male
Middle Aged
Mutation
Prognosis
Protein p53/*analysis/genetics
Survival Rate
Tumor Markers, Biological/analysis
Tumor Suppressor Proteins/*analysis